The ratio of LTA4H to METRNL in the assessment of polycystic ovary syndrome

JP2025525625A5Pending Publication Date: 2026-07-13F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025503356
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-07-22
Filing Date
2023-07-20
Publication Date
2026-07-13

AI Technical Summary

Technical Problem

Current diagnostic methods for polycystic ovary syndrome (PCOS) are inconsistent, require specialized expertise, and lack universal biomarkers for accurate diagnosis, particularly in adolescents and young women, leading to underdiagnosis and overdiagnosis, and are challenging due to overlapping symptoms with normal pubertal changes.

Method used

The use of leukotriene A4 hydrolase (LTA4H) and meteorin-like protein (METRNL) as biomarkers to determine their concentrations in a sample, calculate a score, and compare it with a reference score for diagnosing PCOS, selecting patients for treatment, and monitoring PCOS progression or treatment response.

Benefits of technology

Provides a reliable and objective diagnostic method for PCOS, enabling timely intervention and minimizing metabolic complications by accurately identifying and monitoring the condition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention relates to a method for diagnosing polycystic ovary syndrome (PCOS) in a subject, the method comprising the steps of: a) determining the amount or concentration of total LTA4H in a sample from the subject; b) determining the amount or concentration of METRNL in a sample from the subject; c) calculating a score of the amounts or concentrations determined in steps a) and b); d) comparing the calculated score with a reference score; and e) diagnosing PCOS in the subject.
Need to check novelty before this filing date? Find Prior Art